Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Kenji MorimotoTadaaki YamadaHayato KawachiMotohiro TamiyaYoshiki NegiYasuhiro GotoAkira NakaoShinsuke ShiotsuKeiko TanimuraTakayuki TakedaAsuka OkadaTaishi HaradaKoji DateYusuke ChiharaIsao HasegawaNobuyo TamiyaNaoya NishiokaYuki KatayamaMasahiro IwasakuShinsaku TokudaTakashi KijimaKoichi TakayamaPublished in: Targeted oncology (2023)
In patients with NSCLC exhibiting poor PS and high PD-L1 expression, ICI plus chemotherapy did not confer PFS or OS benefit compared with pembrolizumab monotherapy.